Fountain Healthcare Partners

Life Science Venture Capital Fund.

[Fountain Healthcare Partners @fhpartners]

MMI earns Gold Edison Award for Symani(R), recognized for expanding access to life-changing surgical treatment options #microsurgery
https://t.co/PqaHimK350

[Fountain Healthcare Partners @fhpartners]

Exciva today announces the appointment of Mark Altmeyer as chairman of its board of directors.

https://t.co/HXvvRnDs18

[Fountain Healthcare Partners @fhpartners]

MMI has announced the first patient enrollment and inaugural robotic-assisted procedure in the FDA-IDE approved REMIND study evaluating microsurgical intervention for Alzheimer’s disease using the Symani® Surgical System.

https://t.co/HQ7H0wuuDr

[Fountain Healthcare Partners @fhpartners]

Exciva has dosed the first patient in SERENADA, its Phase 2/3 trial of Deraphan for agitation in Alzheimer’s disease, marking a key clinical inflection point for the company.

https://t.co/RpJjBSRsc0

[Fountain Healthcare Partners @fhpartners]

MMI Introduces World’s First Microsurgical Suture for Robotics https://t.co/ATLCXXWGGJ

[Fountain Healthcare Partners @fhpartners]

XyloCor Appoints John Tucker as President and Chief Executive Officer https://t.co/WuRqskEqVq

[Fountain Healthcare Partners @fhpartners]

Neurent Medical Announces Publication of Positive Randomized Controlled Trial Results for the NEUROMARK® System https://t.co/AUmyIK2zTN

[Fountain Healthcare Partners @fhpartners]

Galway’s Neurent Medical closes €62.5m oversubscribed Series C round https://t.co/TMbSmmHYOO via @siliconrepublic

[Fountain Healthcare Partners @fhpartners]

Neurent raises $74M to commercialize treatment for nasal condition https://t.co/objxJlRzPW via @MedTechDive

[Business Post @businessposthq]

Galway-based medtech Neurent Medical lands mega €62.5m funding round https://t.co/vE4BNr0hdz

[Fountain Healthcare Partners @fhpartners]

Neurent Medical Raises €62.5 million in Oversubscribed Series C Financing to Accelerate NEUROMARK® Commercial Expa... https://t.co/LLEUnv8oon

[Fountain Healthcare Partners @fhpartners]

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota - https://t.co/zGv4FlAqUi

[Fountain Healthcare Partners @fhpartners]

Delighted to participate in Exciva's €51M Series B financing to fund a Phase II trial of Deraphan in the treatment of Alzheimer's Agitation
#Alzheimers
https://t.co/z8WFJj36J6

[Business Post @businessposthq]

Vivasure, a Galway-based medtech company, has been acquired in a deal valued at up to €185 million by US-listed Haemonetics
https://t.co/36vL3HW82W.

[Haemonetics Corp @HaemoneticsCorp]

Today, we closed on our agreement to acquire Vivasure Medical. We're excited to welcome the Vivasure team to Haemonetics & begin working to bring the benefits of the PerQseal® Elite Technology to more clinicians and patients around the world. https://t.co/iitvU698kS #MakeItMatter

[Fountain Healthcare Partners @fhpartners]

Galway medtech Vivasure acquired in deal worth up to €185m https://t.co/xVHfCgwsnn

[Fountain Healthcare Partners @fhpartners]

Haemonetics acquires Vivasure Medical. - https://t.co/aXXgS0xXPk

[Fountain Healthcare Partners @fhpartners]

Mainstay Medical Announces Coverage Recommendation from the International Society for the Advancement of Spine Surgery (ISASS) for ReActiv8 - https://t.co/ST1fsFPkXH

[Fountain Healthcare Partners @fhpartners]

MMI Wins FDA Clearance and Completes First U.S. Clinical Use of Robotic Microsurgical Dissection Instruments with Symani https://t.co/pZbtNdNJ0L

[Fountain Healthcare Partners @fhpartners]

MMI gets IDE for robotic microsurgical study in Alzheimer’s https://t.co/6kCgNHnZOv